GlassScriptPhysician profile
Kumarasamy Sivakumar
NPI 1083762884
$1,920.77
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $1,007 · 2021: $422.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $492.43 | 2019-2021 | |
| Glaxosmithkline, LLC. | $198.87 | 2020-2021 | |
| Amgen INC. | $153.13 | 2019-2021 | |
| Allergan, INC. | $147.52 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $129.77 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $126.38 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.64 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $94.44 | 2019-2021 | |
| Lilly USA, LLC | $86.80 | 2020-2021 | |
| Abbvie INC. | $77.79 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $75.67 | 2019-2020 | |
| Pfizer INC. | $45.56 | 2020 | |
| Depuy Synthes Sales INC. | $44.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.10 | 2019 | |
| Merck Sharp & Dohme LLC | $34.09 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Osiris Therapeutics INC. | $20.15 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.54 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.41 | 2019 | |
| Organogenesis INC. | $12.40 | 2019 | |
| Smith+Nephew, INC. | $10.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumarasamy Sivakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.